Sana Biotechnology, INC 10-Q quarterly reports

Sana Biotechnology, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $47.2 million and highlighting progress in its cell engineering platforms while acknowledging substantial doubt about its ability to continue as a going concern.

Sana Biotechnology, Inc. reported a significant reduction in net losses for the nine months ended September 30, 2025, driven by strategic portfolio prioritization and workforce reductions, while advancing key cell engineering programs.

Sana Biotechnology reports reduced net losses and a strengthened cash position following strategic portfolio prioritization and recent capital raises, despite ongoing development-stage challenges.

Sana Biotechnology announces Q1 2025 results with a net loss of $49.4 million and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Sana Biotechnology reports its Q3 2024 financial results and announces a strategic shift to prioritize certain clinical programs and reduce workforce.

Sana Biotechnology's second quarter 2024 results show a decrease in operating expenses and a net loss of $50.3 million, alongside updates on clinical trials and strategic focus.

Sana Biotechnology's first quarter 2024 results show increased operating expenses and a net loss, alongside a significant increase in cash and marketable securities due to recent equity financings.